Drug Development

Combination Therapy Eli Lilly Targeted Therapy Alzheimer's Treatments Phase 3 Trials Phase III Trials Patient Outcomes Oral Medications Novo Nordisk Targeted Therapies Late-Stage Trials Efficacy Studies Phase 1/2 Trials Antibody Drug Conjugates FDA Approval Regulatory Approval Chronic Spontaneous Urticaria Therapeutic Candidates Duchenne Muscular Dystrophy Lenacapavir Lecanemab Alzheimer's Disease Azelaprag Orforglipron Phase 2 Trials Antibody-Drug Conjugates Cognitive Impairment Biologic Drugs Amyloid Drugs V-DIFFERENCE Trial Gantenerumab Gene Therapy CNS Disorders Baxdrostat Safety and Efficacy Antibody Therapy LUT014 ASITI-201 RAS Inhibitors COPD Treatments Therapeutic Strategies Immunotherapy Orphan Drug Designation Lecanemab Clinical Trials Hereditary Angioedema Hydrogels DKK1 Blockade FDA Approval Process Repurposed Medications AstraZeneca IgA Nephropathy Dementia Treatments Systemic Lupus Erythematosus Blenrep Long-acting Therapies Antibiotic Research Biotechnology Kinase Inhibitors Weight Loss Medications Intracranial Endpoints Innovative Therapies TAR-200 Rocatinlumab Morpholino Novartis and MMV Collaboration Experimental Drugs PP405 Trials Gedatolisib Safety Testing Neuropsychiatric Drugs Weight-loss Pills Africa-led Trials Preclinical Testing Combination Treatments Infant Health Patient-Derived Xenografts AMT-130 NRTTI Research Gilead Sciences Diabetes Medications Sonelokimab Phase 3 Studies Regulatory Pathways Autoimmune Disorders Elinzanetant Phase II Trials Oncology Treatments Stargardt Disease Semaglutide Immunomodulatory Drugs Aficamten ARQ-234 Eosinophilic Esophagitis Friedreich's Ataxia Tumor Treatment Precision Medicine Ulcerative Colitis New Medications TROPION-Breast02 Trial Lymphoma Treatments